Dupilumab for Prurigo Nodularis: Real-World Outcomes Up to 104 Weeks from the DUPItaPN Study - PubMed
4 hours ago
- #prurigo nodularis
- #real-world evidence
- #dupilumab
- Dupilumab significantly reduced itch (WI-NRS from 8.7 to 1.7) and skin lesions (IGA PN-S 0/1 achieved by 81.2%) in prurigo nodularis patients over 104 weeks.
- The treatment improved quality of life (DLQI from 17.4 to 2.6) and sleep, with high response rates (≥4-point WI-NRS reduction in 86.8% of patients at 104 weeks).
- Higher baseline itch severity predicted better outcomes, while psychiatric comorbidities and prior tricyclic antidepressant use were associated with lower response.
- Dupilumab demonstrated a favorable safety profile, with only 2.9% discontinuation due to adverse events and no cancer progression or viral reactivation.
- The real-world study supports dupilumab as an effective long-term therapy for moderate-to-severe PN, including elderly and comorbid patients.